ProCE Banner Activity

Phase Ib Study of ELA026, an Anti-SIRP-α/β/γ mAb, in Patients With Secondary Hemophagocyctic Lymphohistiocytosis

Conference Coverage
Slideset

A phase Ib study of the anti-SIRP monoclonal antibody, ELA026, reported tolerable safety and promising efficacy in frontline settings for patients with sHLH.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation